Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC

The seven-year results from the CROWN trial position LORBRENA as a leading treatment option for advanced NSCLC, significantly impacting clinical practice and competitive dynamics in the oncology space. This data not only enhances Pfizer's market position but also sets a new standard for treatment expectations in this patient population.

The seven-year results from the CROWN trial position LORBRENA as a leading treatment option for advanced NSCLC, significantly impacting clinical practice and competitive dynamics in the oncology space. This data not only enhances Pfizer's market position but also sets a new standard for treatment expectations in this patient population.

Trial Update

The seven-year analysis of the CROWN trial shows a 55% likelihood of remaining alive without disease progression for patients treated with LORBRENA, with median progression-free survival not reached.

The seven-year results from the CROWN trial position LORBRENA as a leading treatment option for advanced NSCLC, significantly impacting clinical practice and competitive dynamics in the oncology space. This data not only enhances Pfizer's market position but also sets a new standard for treatment expectations in this patient population.

Monitor for further data on overall survival and additional long-term outcomes from the CROWN trial, as well as competitive responses from other ALK inhibitors.